Longitudinal Study of Gene Expression in the Human Placenta During First-trimester and Full-term Pregnancy at the Single Cell Level
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · May 16, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how genes in the placenta change during different stages of pregnancy, specifically during the first trimester and at full-term delivery. Researchers want to understand the way these genes work at a very detailed level, using a new method that allows them to look at single cells within the placenta. This research could help improve our understanding of pregnancy and placental health.
To participate in this study, women aged 18 to 50 who are between 11 and 15 weeks pregnant with a single baby may be eligible. Participants must have a medical reason for needing a test called a chorionic villus biopsy, which helps assess genetic conditions, and they should be scheduled to deliver at Port-Royal Maternity Hospital. If you join the study, you will provide small samples of the placenta for analysis. While the study is currently not recruiting participants, it aims to gather important information about how the placenta functions during pregnancy, which could benefit future mothers and babies.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age 18 to 50
- • Progressive monofoetal pregnancy between 11 and 15 weeks of amenorrhea
- • Patient with prenatal medical indication and requesting chorionic villus biopsy with cytogenetic analysis or molecular genetics
- • Patient scheduled for delivery at Port-Royal Maternity Hospital
- Exclusion Criteria:
- • Minor patient
- • Multiple pregnancy
- • Patient's objection
- • Without health insurance
- • Patient under guardianship or curatorship
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, Idf, France
Patients applied
Trial Officials
Céline MÉHATS, PHD
Study Director
Institut National de la Santé Et de la Recherche Médicale, France
Hélène COLLINOT, MD
Principal Investigator
APHP
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported